PHARMACOECONOMIC ANALYSIS OF NEUROPROTECTIVE DRUGS IN THE TREATMENT OF ACUTE DISORDERS OF CEREBRAL CIRCULATION

• Main Authors: A. Yu. Kulikov, I. Yu. Zinchuk
• Format: Article
• Language: Russian
• Published: IRBIS LLC 2015-03-01
• Series: Фармакоэкономика
• Subjects: фармакоэкономический анализ; острое нарушение мозгового кровообращения; нейропротективные препараты; анализ «минимизация затрат»; анализ «затраты- эффективность»
• Online Access: https://www.pharmacoeconomics.ru/jour/article/view/60

Based on meta-analysis dates found, that the effectiveness of neuroprotective drugs and placebo are not differences or has not statistically significant relative placebo. The cost minimization analysis showed that only Cytoflavin and Tserakson, by reducing the time of hospital treatment, reduce the cost as compared to placebo at 22311 RUB and 21345 RUB, respectively. Cost effectiveness analysis, based on the clinical practice in Russia. It is shown, that when survival used as a criterion for effectivenessevaluation, Cytoflavin with CER175003 RUB has the advantage.It was determined that the preferred scheme of treatment of acute ischemic drug is Cytoflavin therapy from the position direct costs reducing and have fewer CER while preserving the patient's life.